<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837353</url>
  </required_header>
  <id_info>
    <org_study_id>17-01747</org_study_id>
    <nct_id>NCT03837353</nct_id>
  </id_info>
  <brief_title>A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1</brief_title>
  <official_title>A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leap Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized multi-center Phase 1b/2a dose escalation and dose expansion study&#xD;
      involving 85-97 patients testing DKN-01 as monotherapy or in combination with docetaxel in&#xD;
      metastatic castration-resistant prostate cancer. Patients need to be biomarker positive&#xD;
      (Dickkopf-1 [DKK1]) either in plasma or biopsy. Other biopsies for correlative studies are&#xD;
      encouraged but not mandatory. Pharmacokinetic (PK) testing of one pre-treatment blood sample&#xD;
      and one post-treatment blood sample will be mandatory on Day 1 of every cycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Dose Limiting Toxicities</measure>
    <time_frame>baseline to End of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Starting from Cohort 1 Day 1 to Cohort 2 Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Dose Limiting Tolerability</measure>
    <time_frame>Baseline to End of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Starting from Cohort 1 Day 1 to Cohort 2 Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of clinical response to treatment</measure>
    <time_frame>Baseline to study completion (approximately 36 Months)</time_frame>
    <description>Repeat tumor imaging confirming PD (iCPD) by iRECIST per Investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities</measure>
    <time_frame>Baseline until 30 days after last dose of study drug as assessments at a minimum of 2 weeks</time_frame>
    <description>Evaluated by NCI CTCAE v 4.0 of DKN-01 monotherapy or in combination with docetaxel</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1A Dose Level 1: DKN-01 300 mg intravenously (IV) on Days 1 and 15, docetaxel 75 mg/m2 on Day 1 every 3 weeks (21- day cycles).&#xD;
Dose Level 2: DKN-01 600 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles).&#xD;
Dose Level -1: DKN-01 150 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1B: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1C: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 1: DKN-01 300 mg IV on Days 1 and 15 of a 28-day cycle. Dose Level 2: DKN-01 600 mg IV on Days 1 and 15 of a 28-day cycle.&#xD;
Dose Level -1: DKN-01 150 mg IV on Days 1 and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2B: DKN-01 at MTD or highest dose tested: Days 1 and 15 (28-day cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKN-01 300 mg</intervention_name>
    <description>DKN-01 300 mg intravenously (IV)</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKN-01 600 mg</intervention_name>
    <description>DKN-01 600 mg IV</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 75 mg/m2</intervention_name>
    <description>Docetaxel 75 mg/m2, Day 1 of every 3 Weeks</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKN-01 150 mg</intervention_name>
    <description>DKN-01 150 mg intravenously (IV)</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologically or cytologically confirmed prostate adenocarcinoma or poorly&#xD;
             differentiated carcinoma of the prostate&#xD;
&#xD;
          -  Surgically or medically castrated, with testosterone levels of &lt; 50 ng/dL (&lt; 2.0 nM).&#xD;
             If the patient is being treated with luteinizing hormone-releasing hormone (LHRH)&#xD;
             agonists (patient who have not undergone orchiectomy), this therapy must have been&#xD;
             initiated at least 4 weeks prior to C1D1 and must be continued throughout the study.&#xD;
&#xD;
          -  Cohorts 1A, 1B, and 1C. Patients must have received 1 or more androgen receptor (AR)&#xD;
             signaling inhibitors (abiraterone or enzalutamide) and have not received prior&#xD;
             taxane-based chemotherapy for prostate cancer. Prior treatment with an AR signaling&#xD;
             inhibitor for castration-sensitive disease will be allowed if the time to progression&#xD;
             was within 1 year after starting drug. Prior treatment with a taxane-based&#xD;
             chemotherapy for castration-sensitive disease will be exclusionary.&#xD;
&#xD;
          -  Cohorts 2A and 2B. Patients must have received 1 or more AR signaling inhibitor&#xD;
             (abiraterone or enzalutamide) and either had disease progression, were intolerant of,&#xD;
             or refused 1 or more taxane-based chemotherapies for mCRPC.&#xD;
&#xD;
          -  Patients must be DKK1-high as determined by either:&#xD;
&#xD;
               1. Elevated DKK1 RNA expression in ≥1% of cells as defined by central laboratory&#xD;
                  testing of a fresh biopsy or archival specimen OR&#xD;
&#xD;
               2. DKK1 protein level in peripheral blood plasma that is above the reference limit&#xD;
                  of a cohort of healthy male controls as established by central laboratory testing&#xD;
&#xD;
          -  Cohort 1B. Patients must have progression of measurable disease per mRECIST v1.1&#xD;
             guidelines.&#xD;
&#xD;
          -  Cohort 1C. Patients must have progression of disease defined as one of the following:&#xD;
&#xD;
               1. PSA progression is defined by Prostate Cancer Working Group 3 (PCWG3) criteria as&#xD;
                  a minimum of two consecutive rising levels, with an interval of ≥1 week between&#xD;
                  each determination with a minimum PSA of 2 ng/mL.&#xD;
&#xD;
               2. Radionuclide bone progression as defined by at least two new metastatic lesions&#xD;
                  (per PCWG3).&#xD;
&#xD;
          -  Cohorts 1A, 2A, 2B. Patients must have baseline progression defined as one of the&#xD;
             following:&#xD;
&#xD;
               1. PSA progression is defined by PCWG3 criteria as a minimum of two consecutive&#xD;
                  rising levels, with an interval of ≥1 week between each determination with a&#xD;
                  minimum PSA of 2 ng/mL.&#xD;
&#xD;
               2. Radionuclide bone progression as defined by at least two new metastatic lesions&#xD;
                  (per PCWG3).&#xD;
&#xD;
               3. Soft tissue progression on transaxial imaging: new or progressive soft tissue&#xD;
                  masses on computed tomography (CT) or magnetic resonance imaging (MRI) scans as&#xD;
                  defined by mRECIST v1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Estimated life expectancy of at least 3 months, in the judgment of the Investigator.&#xD;
&#xD;
          -  Disease-free of active second/secondary or prior malignancies for ≥2 years with the&#xD;
             exception of currently treated basal cell, squamous cell carcinoma of the skin, or&#xD;
             carcinoma in-situ of the cervix or breast.&#xD;
&#xD;
          -  Required initial laboratory values within 14 days of C1D1:&#xD;
&#xD;
               1. Total bilirubin within normal limits for the institution. (For Cohorts 2A and 2B,&#xD;
                  total bilirubin &lt; 3 × ULN is acceptable with known liver metastases).&#xD;
&#xD;
               2. Transaminases [aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
                  (ALT)] ≤1.5 × the upper limit of normal (ULN) OR alkaline phosphatase ≤2.5 × ULN&#xD;
                  (For Cohorts 2A and 2B, AST and ALT and alkaline phosphatase ≤ 5.0 × ULN is&#xD;
                  acceptable with known liver metastases).&#xD;
&#xD;
               3. Creatinine ≤2.0 or calculated creatinine clearance ≥50 mL/min using the Cockcroft&#xD;
                  and Gault Method (Cockroft and Gault 1976).&#xD;
&#xD;
               4. Absolute neutrophil count ≥1000 cells/μl.&#xD;
&#xD;
               5. Absolute lymphocyte count ≥500/μl.&#xD;
&#xD;
               6. Hemoglobin ≥9.0 g/dL.&#xD;
&#xD;
               7. Platelet count ≥100,000 cells/μl. (For Cohorts 2A and 2B, Platelet count ≥75,000&#xD;
                  cells/μl).&#xD;
&#xD;
               8. International normalized ratio (INR) (prothrombin time [PT])/ partial&#xD;
                  thromboplastin time (PTT) ≤1.2 × ULN unless receiving anticoagulant, in which&#xD;
                  case INR ≤3.0 and no active bleeding, (ie, no clinically significant bleeding&#xD;
                  within 14 days prior to first dose of study therapy.&#xD;
&#xD;
          -  Sexually active male patients must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control) during the study and for 6 months after their last&#xD;
             dose of study drug. Should a patient's partner become pregnant or suspect she is&#xD;
             pregnant while participating in the study, the Investigator should be immediately&#xD;
             informed.&#xD;
&#xD;
          -  Reliable and willing to make themselves available for the duration of the study and&#xD;
             are willing to follow study-specific procedures.&#xD;
&#xD;
          -  Provided written informed consent prior to any study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any anti-cancer therapy (with the exception of luteinizing hormonereleasing hormone&#xD;
             [LHRH] analog or antagonist) within 2 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  Any investigational anti-cancer therapy within 4 weeks of initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  Histological small cell or pure neuroendocrine carcinoma that has not yet been treated&#xD;
             with at least one line of platinum-based chemotherapy (Prostate adenocarcinoma with&#xD;
             immunohistochemical neuroendocrine differentiation but without histological small cell&#xD;
             that is naïve to platinumbased chemotherapy will be allowed.)&#xD;
&#xD;
          -  New York Heart Association Class III or IV heart failure, or myocardial infarction&#xD;
             within the past 6 months, or unstable arrhythmia within 3 months.&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry.&#xD;
&#xD;
          -  Known to be human immunodeficiency virus (HIV) positive, have positive hepatitis B&#xD;
             surface antigen (HBSAg), or positive hepatitis C antibody (HCAb) test. (Hepatitis C&#xD;
             antibody-positive patients with an undetectable hepatitis C virus (HCV) RNA will be&#xD;
             eligible.)&#xD;
&#xD;
          -  History of solid organ transplant (ie, heart, lungs, liver, or kidney).&#xD;
&#xD;
          -  History of autologous/allogenic bone marrow transplant.&#xD;
&#xD;
          -  Serious nonmalignant disease that could compromise protocol objectives in the opinion&#xD;
             of the Investigator and/or Sponsor.&#xD;
&#xD;
          -  Major surgical procedures or significant traumatic injury within 4 weeks prior to&#xD;
             study entry (minor procedures within 1 week of study entry).&#xD;
&#xD;
          -  History of osteonecrosis of the hip. Other hip pathology such as degenerative disease&#xD;
             or malignant involvement are not exclusionary. Screening of asymptomatic patients is&#xD;
             not required.&#xD;
&#xD;
          -  Active or untreated central nervous system (CNS) malignancy or metastasis. Screening&#xD;
             for CNS metastases of asymptomatic patients without a history of CNS metastases is not&#xD;
             required. Patients with treated&#xD;
&#xD;
          -  CNS metastases are eligible provided they meet all of the following criteria:&#xD;
&#xD;
               1. Evaluable disease outside the CNS.&#xD;
&#xD;
               2. No history of intracranial or intraspinal hemorrhage.&#xD;
&#xD;
               3. No evidence of significant vasogenic edema.&#xD;
&#xD;
               4. No ongoing requirement for corticosteroids as therapy for CNS disease.&#xD;
                  (Anti-convulsants at a stable dose for &gt; one month is allowed.)&#xD;
&#xD;
               5. No stereotactic radiation, whole brain radiation within 4 weeks of C1D1.&#xD;
&#xD;
               6. Patients with CNS metastases treated by neurosurgical resection or brain biopsy&#xD;
                  within 3 month prior to C1D1 will not be allowed.&#xD;
&#xD;
               7. Radiographic demonstration of interim stability (ie, no progression) between&#xD;
                  completion of CNS-directed therapy and the screening radiographic study.&#xD;
&#xD;
               8. Screening CNS radiographic study ≥4 weeks since completion of radiotherapy or&#xD;
                  surgical resection and ≥2 weeks since discontinuation of corticosteroids.&#xD;
&#xD;
          -  Any other condition, disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complications.&#xD;
&#xD;
          -  Active substance abuse.&#xD;
&#xD;
          -  Receipt of any live vaccine within 30 days before the first dose of study treatment or&#xD;
             anticipation that such a live vaccine will be required during study.&#xD;
&#xD;
          -  Previously treated with an anti-DKK1 therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wise, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casey Konys</last_name>
    <phone>(212)-263-1208</phone>
    <email>casey.konys@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Aggarwal, MD</last_name>
      <email>Rahul.Aggarwal@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Denmeade, MD</last_name>
      <email>DENMESA@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Denmeade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Pachynski, MD</last_name>
      <email>rkpachynski@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Pachynski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs New York Harbor Healthcare System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Becker, MD</last_name>
      <email>Daniel.Becker@va.gov</email>
    </contact>
    <investigator>
      <last_name>Daniel Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wise, MD, PhD</last_name>
      <email>David.Wise@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>David Wise, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

